Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Withdrawn 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 120Neoplasms 75Prostatic Neoplasms 70Lung Neoplasms 36Carcinoma, Non-Small-Cell Lung 33Pancreatic Neoplasms 32Colorectal Neoplasms 32Head and Neck Neoplasms 29Carcinoma, Hepatocellular 24Brain Neoplasms 24Colonic Neoplasms 22Motor Activity 19Carcinoma, Renal Cell 18Pain 16Ovarian Neoplasms 16Neoplasm Metastasis 14Hematologic Neoplasms 14Urinary Bladder Neoplasms 13Rectal Neoplasms 13Lymphoma, Follicular 13Fatigue 13Sarcoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Glioblastoma 12Lymphoma 11Liver Neoplasms 11Glioma 11Squamous Cell Carcinoma of Head and Neck 10Leukemia 10Anxiety Disorders 10

Interventions

transplatin 1Platinum 1Gemcitabine 1Cystectomy 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × Withdrawn × Infiltrating Bladder Urothelial Carcinoma × Clear all
NCT02688348 2020-07-24

Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients With Muscle-Invasive Bladder Cancer

Jonsson Comprehensive Cancer Center

Phase NA Withdrawn
Genitourinary

Infiltrating Bladder Urothelial Carcinoma

NCT02944357 2017-11-17

Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery

Mayo Clinic

Phase NA Withdrawn
Genitourinary

Infiltrating Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡